|Articles|May 18, 2004

FDA clears I-ReadMammo

Cedara has received FDA clearance for its I-ReadMammo breast imaging workstation. The new product, which supports images from multiple modalities and various mammography vendors (SCAN 5/5/04), will begin shipping this summer. It will be marketed directly

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Related to this article

October 9th, 2026

The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 3

In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.

October 9th, 2026

What New Dosimetry Data Reveals About 177Lu-Edotreotide for GEP-NET Treatment

In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.

October 8th, 2026

The Responsibility of Authorship in the AI Era

While AI offers the lure of efficiency and cleaner writing in scientific research, maintaining the principles of authorship and intellectual engagement is perhaps more important than ever before.

October 7th, 2026

FDA Clears AI-Powered Platform for Converting Spine MRIs to 3D Visualizations

The cloud-based NextMR platform reportedly provides automated 3D bone images of conventional spine MRI images in less than 60 seconds.

October 7th, 2026

Study Shows Impact of Key mpMRI Features for Enhancing Assessment of Renal Masses

Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.

October 6th, 2026

Tumor Margin Marker on Contrast-Enhanced Ultrasound May Predict Worse Outcomes in Patients with HCC

For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.

October 6th, 2026

Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia

In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.

October 6th, 2026

FDA Clears MRI-Based AI Software for Body Composition Analysis

The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.

FDA clears I-ReadMammo

Related to this article

Trending on Diagnostic Imaging

The Responsibility of Authorship in the AI Era

What New Dosimetry Data Reveals About 177Lu-Edotreotide for GEP-NET Treatment

FDA Clears AI-Powered Platform for Converting Spine MRIs to 3D Visualizations

FDA Clears MRI-Based AI Software for Body Composition Analysis

The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 3